Related Experiment Video
Updated: Aug 7, 2026

Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy
Published on: October 19, 2016
Aortic stiffness correlates with an increased extracellular matrix turnover in patients with dilated cardiomyopathy
Stefano Bonapace1, Andrea Rossi, Mariantonietta Cicoira
1Divisione Clinicizzata di Cardiologia, Dipartimento di Scienza Biomediche e Chirurgiche, Università di Verona, Verona, Italy.
Insights
Increased collagen turnover, indicated by serum aminoterminal propeptide of type III collagen (PIIINP), is linked to aortic stiffness in dilated cardiomyopathy (DCM) patients. This finding may explain progressive large artery stiffening in chronic heart failure (CHF).
Area of Science:
- Cardiovascular Medicine
- Biomarkers
- Extracellular Matrix Biology
Background:
- Increased extracellular matrix (ECM) turnover is linked to poor survival in chronic heart failure (CHF) with dilated cardiomyopathy (DCM).
- The impact of accelerated collagen turnover on aortic stiffening in DCM remains unclear.
- Aortic stiffening worsens systolic load and reduces exercise tolerance in CHF patients.
Purpose of the Study:
- To investigate the association between serum aminoterminal propeptide of type III collagen (PIIINP) and aortic stiffness in DCM patients.
- To determine if PIIINP, a marker of ECM turnover, relates to aortic pulse-wave velocity (PWV) in DCM.
Main Methods:
- Eighty-nine DCM patients were analyzed.
- Aortic pulse-wave velocity (PWV) was measured using Doppler ultrasonography.
- Serum PIIINP concentrations were quantified via radioimmunoassay.
Main Results:
- Mean aortic PWV was 5.7 m/s and mean PIIINP was 5.0 microg/L.
- Aortic PWV correlated with age, PIIINP, heart rate, stroke volume, and NYHA class.
- Multivariate analysis revealed age and PIIINP as independent predictors of aortic PWV, explaining 27% of its variance.
Conclusions:
- Elevated serum PIIINP levels are independently associated with increased aortic stiffness in DCM patients.
- ECM turnover abnormalities may affect proximal elastic arteries, contributing to aortic stiffening in CHF.
- PIIINP may serve as a potential biomarker for assessing aortic stiffness in DCM.
Background:
An increased extracellular matrix (ECM) turnover has been associated with poor survival in patients with chronic heart failure (CHF) due to dilated cardiomyopathy (DCM). However, the influence of the accelerated collagen turnover on the progressive large artery stiffening process characterizing CHF has not been clarified. This is relevant because aortic stiffening imposes an additional systolic load and impairs exercise tolerance in CHF patients. Therefore, we investigated whether the serum aminoterminal propeptide of type III collagen (PIIINP), an established marker of ECM turnover and tissue fibrosis in DCM, was associated with aortic stiffness in DCM patients.
Methods And Results:
A total of 89 patients with clinical diagnosis of DCM (age 62 +/- 9 years, 80% men, mean ejection fraction 34% +/- 8%) were selected. Aortic pulse-wave velocity (PWV), a well-established marker of aortic stiffness, was measured by Doppler ultrasonography. Serum concentration of PIIINP was determined by radioimmunoassay. Mean aortic PWV was 5.7 +/- 2.3 m/s, and PIIINP was 5.0 +/- 1.3 microg/L. The variables correlated with aortic PWV were age (r = 0.33, P = .002), PIIINP (r = 0.30, P = .005), heart rate (r = 0.27, P = .02), stroke volume (r = -0.24, P = .03) and New York Heart Association class (r = 0.25, P = .02). In a multivariate analysis, age (P = .02) and PIIINP (P = .01) were independently related with aortic PWV, accounting for 27% of its variance.
Conclusions:
Higher serum PIIINP levels are independently associated with a stiffer aorta in DCM patients. This suggests that abnormalities in the ECM turnover might involve the proximal elastic vasculature and could partially explain the progressive large artery stiffening process characterizing CHF.
Related Concept Videos
Extracellular Matrix
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure II: Pathophysiology
Atherosclerosis I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy

